XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > No news YET , up 20% , now 0.60 , soon a Dollar

<< Previous

Bullboard Posts

Next >>

Comment by Richmondon Sep 15, 2021 7:47pm

99 Views

Post# 33866542

RE:RE:No news YET , up 20% , now 0.60 , soon a Dollar

RollBack 5:1............or ZERO rollback if Covid-19 AKD DRUG (cure for Kidney affected by Covid-19) gets patented after phase 3...trials. XORTEX can go through the roof!!!